Nucresiran vs Patisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Polyneuropathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline

Nucresiran

Developed by Alnylam Pharmaceuticals

Phase 3 in Transthyretin Amyloidosis with PolyneuropathyRNAi
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2027 · NCT07223203 (registry estimate)

No aligned efficacy figure on record for this race.

Patisiran · ONPATTRO

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with PolyneuropathyRNAi
Reliable signal

NCT01960348 · Phase 3 · completed

In this randomized, double-blind, placebo-controlled phase 3 trial, 225 participants received patisiran (148) or placebo (77). The hard clinical primary endpoint, change in mNIS+7 at 18 months, favored patisiran and was statistically significant: -6.03 versus 27.96 points, a between-group difference of -33.99 (p<0.0000001).

Reported efficacy

Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) (met)

Result source: NCT01960348

Results for Transthyretin Amyloidosis with Polyneuropathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Polyneuropathy.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Patisiran
Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) NCT01960348 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nucresiran's landscape · Patisiran's landscape